The Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Treatment Market is estimated to be valued at US$ 748.80 million in 2022 and is
expected to exhibit a CAGR of 31.1% over the forecast period 2023-2030, as
highlighted in a new report published by Coherent Market Insights.
Market Overview:
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive heart muscle
disease caused by the buildup of abnormal deposits of amyloid protein in the
heart. Treatment options target the underlying cause by modifying disease
progression or alleviating symptoms to improve quality of life.
Market Dynamics:
The growth of the ATTR-CM treatment market is driven by the rising number of
patients diagnosed with ATTR-CM and the approval of novel drugs for treatment.
According to studies, diagnosis rates are increasing thanks to more widespread
clinical awareness and the availability of non-invasive diagnostic tools.
Additionally, several pharmaceutical companies are investing heavily in R&D
to develop new precision medicines for ATTR-CM, with a few therapies recently
receiving approval and many others in clinical trials. This expanding treatment
landscape is set to propel market growth over the forecast period.
Market
key trends:
The Transthyretin Amyloid Cardiomyopathy
(ATTR-CM) Treatment Market has been witnessing a rise in research and
development activities for innovative treatment options. ATTR-CM usually
affects the heart and is caused due to a buildup of abnormal deposits of
amyloid protein called transthyretin in the heart tissue. conventional
treatments have limited efficacy in halting or reversing the progression of
heart muscle damage. Hence, new drug candidates that can prevent the
aggregation of misfolded transthyretin protein are being researched. Gene
silencing therapies have emerged as a promising treatment approach and are in
clinical trials.
SWOT Analysis
Strengths: robust pipeline of drug candidates in clinical trials, increasing
awareness about ATTR-CM condition.
Weaknesses: high treatment costs, conventional drugs have limited efficacy.
Opportunities: demand for effective treatments, growth in geriatric population
susceptible to ATTR-CM.
Threats: regulatory hurdles for approval of new drugs, pricing pressure on
pharmaceutical companies.
Key Takeaways
North America currently dominates the ATTR-CM treatment market owing to
presence of major pharmaceutical companies involved in research and approvals.
The region is expected to retain its leading position during the forecast
period.
Key players operating in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Treatment Market incorporate Pfizer Inc., GlaxoSmithKline Plc., Eidos
Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena
Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc.
Comments
Post a Comment